18.03.2013F2G Ltd. Appoints Ian Nicholson as Chief Executive Officer Manchester


F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors .

Press Release
19.12.2012CN Creative acquired by British American Tobacco

Press Release
19.12.2012British American Tobacco buys UK based e-cigarette technology company

Press Release
17.12.2012Advent Life Sciences Announces Appointment of Ian Nicholson as Operating Partner

Press Release
14.12.2012Algeta’s partner Bayer submits New Drug Application to US FDA for Radium-223 Dichloride

Press Release
12.12.2012Biocartis completes €34,5million ($44,5 million) Series D Fund Raising

Press Release
12.12.2012Algeta’s partner Bayer submits Radium-223 Dichloride for EU Marketing Authorisation

Submission to trigger €50 million milestone payment to Algeta

Press Release
05.12.2012Biocartis announces commercial launch of a new biomarker analysis platform

Press Release
05.09.2012F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds

Antifungal drug discovery and development company announces the completion of a $30 million equity financing round

Press Release
20.07.2012First gene therapy in Western world receives positive opinion in Europe from CHMP

Press Release